Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID‐19

A 69‐year‐old man with a history of type 2 diabetes and high blood pressure was diagnosed with coronavirus disease 2019 (COVID‐19). He had hyperferritinaemia and respiratory failure. Despite the initiation of favipiravir and high‐dose corticosteroid and ceftriaxone, his respiratory failure progresse...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishiwari, Mayuko, Togashi, Yuki, Takoi, Hiroyuki, Kikuchi, Ryota, Kono, Yuta, Abe, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604553/
https://www.ncbi.nlm.nih.gov/pubmed/33163186
http://dx.doi.org/10.1002/rcr2.679
Descripción
Sumario:A 69‐year‐old man with a history of type 2 diabetes and high blood pressure was diagnosed with coronavirus disease 2019 (COVID‐19). He had hyperferritinaemia and respiratory failure. Despite the initiation of favipiravir and high‐dose corticosteroid and ceftriaxone, his respiratory failure progressed and serum ferritin levels increased. After polymyxin B‐immobilized fibre column direct haemoperfusion (PMX‐DHP) therapy, there was improvement of the respiratory failure and hyperferritinaemia. We report the first case of COVID‐19‐induced hyperferritinaemia and severe respiratory failure successfully treated by PMX‐DHP.

Ejemplares similares